Inhibrx (NASDAQ:INBX – Get Free Report) will likely be announcing its earnings results before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($2.88) per share for the quarter.
Inhibrx Price Performance
Shares of NASDAQ:INBX opened at $12.49 on Tuesday. Inhibrx has a 12 month low of $10.80 and a 12 month high of $18.95. The stock’s 50 day moving average price is $13.78 and its 200 day moving average price is $14.59.
Wall Street Analyst Weigh In
Separately, JMP Securities reissued a “market perform” rating on shares of Inhibrx in a report on Wednesday, January 22nd.
About Inhibrx
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Read More
- Five stocks we like better than Inhibrx
- What Are Treasury Bonds?
- The Behemoth BlackRock’s Next Trillion Comes From Private Assets
- What is a SEC Filing?
- Rivian’s Rough Patch: Is the Dip a Doorway to Long-Term Gains?
- Trading Stocks: RSI and Why it’s Useful
- Institutions Signal Opportunty to Buy High-Yield Kraft-Heinz
Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.
